Mustang Bio Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
MBIO
- Share Price
-
$0.35
- (As of Friday Closing)
Mustang Bio General Information
Description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Contact Information
Website
www.mustangbio.comCorporate Office
- 95 Sawyer Road
- Suite 110
- Waltham, MA 02453
- United States
Corporate Office
- 95 Sawyer Road
- Suite 110
- Waltham, MA 02453
- United States
Mustang Bio Timeline
Mustang Bio Stock Performance
As of 20-Nov-2026, Mustang Bio’s stock price is $0.35. Its current market cap is $2.69M with 7.58M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.35 | $0.37 | $0.35 - $1.43 | $2.69M | 7.58M | 33.3K | -$0.51 |
Mustang Bio Financials Summary
As of 30-Sep-2026, Mustang Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (11,642) | (11,824) | 13,572 | 61,378 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,956) | (2,391) | (15,108) | (48,914) |
| Net Income | (3,529) | (1,921) | (15,752) | (51,602) |
| Total Assets | 14,683 | 17,593 | 9,308 | 17,742 |
| Total Debt | 0 | 0 | 878 | 2,498 |
Mustang Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mustang Bio Comparisons
Industry
Financing
Details
Mustang Bio Competitors (84)
One of Mustang Bio’s 84 competitors is Caribou Biosciences, a Formerly VC-backed company based in Berkeley, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Vor Biopharma | Formerly VC-backed | Boston, MA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
Mustang Bio Patents
Mustang Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021342126-A1 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Inactive | 10-Sep-2020 | ||
| AU-2021342126-A9 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Inactive | 10-Sep-2020 | ||
| CA-3194747-A1 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | ||
| EP-4210831-A2 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Inactive | 10-Sep-2020 | ||
| US-20220072043-A1 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | A61K40/31 |
Mustang Bio Signals
Mustang Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mustang Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.55 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Mustang Bio FAQs
-
When was Mustang Bio founded?
Mustang Bio was founded in 2015.
-
Where is Mustang Bio headquartered?
Mustang Bio is headquartered in Waltham, MA.
-
What is the size of Mustang Bio?
Mustang Bio has 4 total employees.
-
What industry is Mustang Bio in?
Mustang Bio’s primary industry is Drug Discovery.
-
Is Mustang Bio a private or public company?
Mustang Bio is a Public company.
-
What is Mustang Bio’s stock symbol?
The ticker symbol for Mustang Bio is MBIO.
-
What is the current stock price of Mustang Bio?
As of 20-Nov-2026 the stock price of Mustang Bio is $0.35.
-
What is the current market cap of Mustang Bio?
The current market capitalization of Mustang Bio is $2.69M.
-
Who are Mustang Bio’s competitors?
Caribou Biosciences, Genetix Biotherapeutics, Vor Biopharma, Allogene Therapeutics, and Poseida Therapeutics are some of the 84 competitors of Mustang Bio.
-
What is Mustang Bio’s annual earnings per share (EPS)?
Mustang Bio’s EPS for 12 months was -$0.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process